Information Provided By:
Fly News Breaks for August 13, 2019
OPTN
Aug 13, 2019 | 07:31 EDT
Cantor Fitzgerald analyst Brandon Folkes says Optinose's "solid" Q2 results last night should bring back Xhance optimism. Despite a "lumpy" initial launch, we are beginning to see Xhance gain traction, which supports confidence in the peak sales potential of the product, Folkes tells investors in a post-earnings research note. He believes increased access, better affordability, the sales force expansion and increased awareness of the "good" efficacy data should continue to drive script growth this year and beyond. The analyst reiterates an Overweight rating on Optinose with a $27 price target.
News For OPTN From the Last 2 Days
There are no results for your query OPTN